<DOC>
	<DOC>NCT02514967</DOC>
	<brief_summary>The purpose of this study is to evaluate the clinical efficacy of blisibimod as measured by a composite responder index in subjects who, despite corticosteroid use, continue to have seropositive, clinically-active Systemic Lupus Erythematosus (SLE) as defined by SELENA-SLEDAI score ≥10, and positive for anti-double stranded DNA and low complement (C3 or C4).</brief_summary>
	<brief_title>CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<mesh_term>Nephritis</mesh_term>
	<criteria>Fulfill at least 4 diagnostic criteria for SLE defined by American College of Rheumatology Active SLE disease as defined by SELENASLEDAI score ≥10 despite ongoing stable corticosteroid therapy Positive for antidouble stranded DNA (antidsDNA) and low complement Subjects with stable nephritis may be enrolled 18 years of age or older Severe active central nervous system lupus Malignancy within past 5 years Known to be positive for HIV and/or positive at the screening visit for hepatitis B, or hepatitis C Comorbidities that would interfere with evaluations of study drug effect Active infection requiring hospitalization or treatment with parenteral antibiotics within the past 60 days or history of repeated herpetic viral infections History of active tuberculosis or a history of tuberculosis infection Pregnant or nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>SLE</keyword>
	<keyword>Lupus</keyword>
	<keyword>Lupus Erythematosus, Systemic</keyword>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>A-623</keyword>
	<keyword>Blisibimod</keyword>
	<keyword>Nephritis</keyword>
</DOC>